查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179874

2023-2030 年全球肌肉骨骼疾病治疗市场

Global Musculoskeletal Diseases Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内 (2023-2030)，肌肉骨骼疾病治疗的全球市场规模预计将以 4.8% 的复合年增长率增长。

肌肉、骨骼、关节和附近结缔组织的功能障碍，导致暂时或永久的功能限制和受累，构成了 150 多种不同的疾病和病症，称为肌肉骨骼疾病。我在这里。 主要的肌肉骨骼疾病比其他常见疾病的治疗费用更高，因为它们通常会导致长期疼痛和残疾。

市场动态

推动全球肌肉骨骼疾病治疗市场的主要因素是肌肉骨骼疾病数量的增加、肌肉骨骼疾病治疗技术的发展以及公众对肌肉骨骼疾病驱动市场的比例的认识提高。有一个东西.

市场的主要驱动力是肌肉骨骼疾病的增加，预计这将推动市场增长。

世界卫生组织估计，到 2022 年，全球将有 17.1 亿人受到肌肉骨骼疾病的影响。 在 160 个不同的国家，背痛是唯一的残疾原因，而肌肉骨骼疾病是全世界残疾的主要原因。 肌肉骨骼疾病严重限制了运动和灵活性，导致提前退休、幸福感下降以及参与社会的能力下降。 由于人口增长和老龄化，患有肌肉骨骼疾病和相关功能受限的人数不断增加。

根据关节炎 2021，英国有超过 2000 万人（约占人口的三分之一）患有肌肉骨骼系统 (MSK) 疾病，例如关节炎和背痛。 患有关节炎等 MSK 疾病的患者通常会感到疲劳、僵硬、行动不便和灵活性下降，以及疼痛，这是这些疾病的主要症状之一。 因此，新兴市场参与者在采用肌肉骨骼疾病疗法方面具有显着的市场领先优势。

高昂的处理成本可能会减缓市场扩张。

市场预计将受到高研发成本和復杂行政程序的阻碍。 此外，医院主要担心的是治疗肌肉骨骼疾病的潜在副作用将使市场停滞。

COVID-19 影响分析

在全球范围内，COVID-19 大流行对医疗保健系统产生了不利影响。 许多行业参与者的活动和业绩受到大流行的影响，活动逐渐减少。 此外，2020年上半年，肌肉骨骼疾病治疗市场受到COVID-19大流行的严重影响。 在大流行的早期阶段，封锁的迅速实施扰乱了分销网络。 此外，由于全世界都在集中精力抗击病毒，肌肉骨骼疾病的治疗也被中断或延迟。 COVID-19 的典型症状类似于风湿病和肌肉骨骼疾病的症状，因此很难对这些症状进行适当和最佳的治疗。

此外，用于治疗 COVID-19 感染的各种抗病毒药物的副作用使问题进一步复杂化。 但在月子事件后，市场逐渐復苏，治疗肌肉骨骼疾病的药物需求增加，加强了供应链。 此外，製药公司正在开发先进的药物来治疗疾病，以便患者可以选择更有效的治疗方法。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 市场的主要驱动因素是肌肉骨骼疾病的增加。
      • 治疗肌肉骨骼疾病的技术发展
    • 约束因素
      • 飙升的治疗费用可能会阻碍市场扩张
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按疾病类型分类

  • 关节炎
  • 骨关节炎
  • 骨质疏鬆症
  • 脊椎炎
  • 创伤性骨折
  • 肌肉减少症
  • 纤维肌痛
  • 其他

第 8 章按成像方式

  • 磁共振成像 (MRI)
  • 计算机断层扫描 (CT)
  • 超声诊断设备
  • 其他

第9章药物

  • 对乙□氨基酚
  • 非甾体抗炎药 (NSAID)
  • 抗神经性止痛药
  • 其他

第 10 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • 辉瑞
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Koninklijke Philips
  • Siemens
  • Canon Medical Systems
  • Hitachi
  • Shimadzu
  • Fujifilm
  • Toshiba
  • Accuray
  • MR Solutions
  • Globus Medical Inc

第14章 DataM

简介目录
Product Code: DMPH6109

Market Overview

The global musculoskeletal diseases treatment market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.8% during the forecast period (2023-2030).

Muscle, bone, joint, and nearby connective tissue dysfunction resulting in temporary or permanent restrictions in functioning and involvement make up over 150 different diseases and conditions known as musculoskeletal impairments. Major musculoskeletal diseases are more expensive to treat than other common medical conditions because they frequently cause long-term pain and disability.

Market Dynamics

The major factors driving the global musculoskeletal diseases treatment market are due to the market is primarily being driven by a rise in the number of musculoskeletal diseases, technological developments in the treatment of musculoskeletal diseases and increasing public awareness of the rate of musculoskeletal diseases.

The market is primarily being driven by a rise in the number of musculoskeletal diseases is expected to drive the market's growth.

World Health Organization estimates that 1.71 billion people worldwide will suffer from musculoskeletal diseases in 2022. Low back pain is the sole cause of disability in 160 different nations, and musculoskeletal diseases are the main cause of disability globally. Musculoskeletal disorders severely restrict movement and dexterity, which results in early retirement from the workforce, decreased levels of well-being, and a decreased capacity to engage in society. The number of people with musculoskeletal diseases and related functional restrictions is constantly rising due to population expansion and aging.

Over 20 million people in the UK (approximately a third of the population), according to versus arthiritis 2021, suffer from musculoskeletal (MSK) conditions like arthritis and low back pain. Patients with MSK diseases like arthritis usually suffer pain, which is one of the main symptoms of these conditions, in addition to fatigue, stiffness, and a loss of movement and dexterity. As a result, key players in developing nations have significant advantages in leading the market by adopting musculoskeletal illness treatment.

The high cost of treatment could slow market expansion.

The market is anticipated to be hampered by expensive R&D expenses and a complicated government process. Additionally, the hospitals' main fear is that the potential for side effects from the treatment of musculoskeletal diseases would halt the market.

COVID-19 Impact Analysis

Globally, the COVID-19 pandemic had a detrimental effect on healthcare systems. Many industry players' activities and financial results have been impacted by the Pandemic and the gradually declining of activities. Additionally, in the first half of 2020, the market for the treatment of musculoskeletal diseases was significantly impacted by the COVID-19 epidemic. During the Pandemic's early stages, the distribution network was hampered by the rapid implementation of lockdown. Furthermore, while the globe concentrated on the virus-fighting effort, treatments for musculoskeletal diseases were suspended or delayed. The typical COVID-19 manifestations, which can mimic the symptoms of rheumatic and musculoskeletal diseases, make it difficult to treat these conditions appropriately and optimally.

Additionally, the side effects of the various antiviral medications used to treat COVID-19 infection further complicate matters. However, the market gradually recovered following the lockdown, which increased the demand for medications for musculoskeletal disorders and strengthened the supply chain. In addition, pharmaceutical companies are developing advanced disease medications to encourage patients to choose more effective therapies.

Segment Analysis

The arthritis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Arthritis is the most prevalent disease type in the musculoskeletal disease treatment market. Inflammation of one or more joints, such as the knees, knuckles, wrists, or ankles, is known as arthritis or joint disease. Joint pain, edema, and stiffness can develop as arthritis progresses from its first stage of joint inflammation. The CDC estimates that approximately 58.5 million Americans, or one out of four US adults (23.7%), have arthritis that a doctor has officially diagnosed.

Women are more likely to have arthritis (23.5%) than men (18.1%), it is more prevalent in adults with fair or poor health (40.5%) than in adults with excellent or very good health (15.4%), and it is less prevalent in adults who meet physical activity guidelines (18.1%) than in adults who are insufficiently active or inactive (23.1% and 23.6%, respectively). Age is a factor in the prevalence of arthritis. Drugs frequently treat arthritis because they can lessen inflammation and persistent pain. Anti-inflammatory drugs sold over the counter and painkillers may reduce arthritic discomfort. Corticosteroids can lower inflammation and suppress the immune system.

Geographical Analysis

North America holds the largest market share in the global musculoskeletal diseases treatment market.

North America dominates the global musculoskeletal diseases treatment market has a major influence on adopting various medical procedures. The treatment of musculoskeletal diseases market is growing in North America due to the rising prevalence of inflammatory bowel diseases and the availability of more hospitals and improved diagnostics facilities. The United States Bone and Joint Initiative (USBJI) predicts that by 2040, 1 in 5 U.S Americans will be 65 or older, roughly equaling the proportion of people in that age group.

Nearly two-thirds of people with arthritis are under 65, even though one in two adults aged 65 and older already has some arthritis. 67 million persons are expected to have arthritis by the year 2030. Both inflammatory types of osteoarthritis and inflammatory forms of arthritis are more common in women. Additionally, over the next few years, it is anticipated that the critical healthcare benefits provided by employer-sponsored health insurance plans and the growing investments by vendors in cutting-edge and affordable medications will boost this regional market.

Competitive Landscape

The musculoskeletal diseases treatment market is moderately competitive with local and global companies' presence Pfizer, Koninklijke Philips, Siemens, Canon Medical Systems, Hitachi, Shimadzu, Fujifilm, Toshiba, Accuray, MR Solutions, Globus Medical and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth.

Globus Medical Inc.

Overview: A manufacturer of medical devices, Globus Medical Inc. (Globus) creates and markets healthcare products for persons with musculoskeletal diseases. The business provides surgical instruments, biologics, accessories, and implanted devices for various spinal, orthopedic, and neurosurgery treatments. Ankle fracture system, clavicle fracture system, distal radius fracture system, proximal tibia fracture system, and small fragment fracture system are some of its main offerings. Additionally, it provides clever computer-assisted systems intended to enhance surgeons' capabilities and simplify surgical procedures.

Product Portfolio:

ANTHEM Ankle Fracture System: Three types of distal fibula plates are available with contours to match patient anatomy and minimize the need for intraoperative bending. Low profile plates are designed for minimal screw prominence to help reduce soft tissue irritation. Clamps designed specifically for ankle anatomy facilitate fracture reduction. Radiolucent Weitlaners and retractors aid in fracture site visibility.

The global musculoskeletal diseases treatment market report would provide access to approx.: 45 + market data table, 40 + figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The market is primarily being driven by a rise in the number of musculoskeletal diseases
      • 4.1.1.2. Technological developments in the treatment of musculoskeletal diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of treatment could slow market expansion
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Arthritis
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Osteoarthritis
  • 7.4. Osteoporosis
  • 7.5. Spondylitis
  • 7.6. Traumatic fractures
  • 7.7. Sarcopenia
  • 7.8. fibromyalgia
  • 7.9. Others

8. By Imaging Modality

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 8.1.2. Market Attractiveness Index, By Imaging Modality
  • 8.2. Magnetic Resonance Imaging (MRI)
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Computed Tomography (CT)
  • 8.4. Ultrasound
  • 8.5. Others

9. By Medication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 9.1.2. Market Attractiveness Index, By Medication
  • 9.2. Acetaminophen
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • 9.4. Anti-neuropathic pain medications
  • 9.5. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacy
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacy
  • 10.4. Online Pharmacy

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Pfizer
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Koninklijke Philips
  • 13.3. Siemens
  • 13.4. Canon Medical Systems
  • 13.5. Hitachi
  • 13.6. Shimadzu
  • 13.7. Fujifilm
  • 13.8. Toshiba
  • 13.9. Accuray
  • 13.10. MR Solutions
  • 13.11. Globus Medical Inc

LIST NOT EXHAUSTIVE

14. Global Musculoskeletal diseases treatment Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us